Free Trial
NASDAQ:PMN

Promis Neurosciences Q2 2023 Earnings Report

Promis Neurosciences logo
$0.40 0.00 (-1.05%)
As of 03:57 PM Eastern

Promis Neurosciences EPS Results

Actual EPS
-$0.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Promis Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Promis Neurosciences Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Sunday, August 13, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

Promis Neurosciences' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Promis Neurosciences Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
See More Promis Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email.

About Promis Neurosciences

Promis Neurosciences (NASDAQ:PMN), Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

View Promis Neurosciences Profile

More Earnings Resources from MarketBeat